Early Serum Free Light Chain Response in Newly Diagnosed Multiple Myeloma: Documented Earlier Than MRD and Complementary in Prognosis
Hematological Oncology · 2026
DOI: 10.1002/hon.70234 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematological Oncology, 2026. Verfasst von Yubiao Pan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Zhongshan Hospital Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Multiple Myeloma, Immunoglobulin Light Chains, Neoplasm, Residual. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Shanghai Municipality.
Abstract (Originalsprache)
Minimal residual disease (MRD) is the standard for deep response assessment in multiple myeloma but requires bone marrow sampling. Whether early serum free light chain (sFLC) response provides independent prognostic information in real‐world, predominantly non‐transplant patients remains unclear. We retrospectively analyzed 701 patients with newly diagnosed multiple myeloma treated at a single Chinese center (2015–2021). sFLC ratio normalization (IMWG range 0.26–1.65) during the first four induction cycles was assessed using a 4‐month landmark to mitigate immortal time bias. Multivariable Cox models adjusted for R‐ISS and age, with prespecified sensitivity analyses and direct comparison with established markers and MRD. Among 701 patients (median age 64 years; ASCT 12.6%), 433 (61.8%) were classified as FLC‐normalized during C1‐C4. FLC non‐normalization was associated with inferior PFS (HR 2.10, 95% CI 1.60–2.76) and OS (HR 1.96, 95% CI 1.32–2.90) after adjustment for R‐ISS stage and age. The association persisted in baseline‐abnormal patients and after MRD adjustment. Adding sFLC status produced a modest improvement in model discrimination, supporting a complementary rather than stand‐alone prognostic role. sFLC normalization was documented earlier than MRD negativity, a pattern that persisted in a paired‐visit‐restricted sensitivity analysis, although timing comparisons remain subject to retrospective assessment schedules. Early sFLC response was associated with outcomes in newly diagnosed multiple myeloma and provided complementary, incremental prognostic information beyond established risk factors and MRD. These findings support further prospective evaluation of sFLC normalization as a pragmatic blood‐based marker for early risk stratification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Zhongshan Hospital Fudan University, Shanghai, China.
ORCID-Profile: Yubiao Pan, Yue Wang, Panpan Li, Chenqi Yu, Peng Liu
Förderung
- Natural Science Foundation of Shanghai Municipality
Zitieren
APA
Pan, Y., Wang, Y., Xiong, Y., Li, P., Yu, C., & Liu, P. (2026). Early Serum Free Light Chain Response in Newly Diagnosed Multiple Myeloma: Documented Earlier Than MRD and Complementary in Prognosis. Hematological Oncology. https://doi.org/10.1002/hon.70234
Vancouver
Pan Y, Wang Y, Xiong Y, Li P, Yu C, Liu P. Early Serum Free Light Chain Response in Newly Diagnosed Multiple Myeloma: Documented Earlier Than MRD and Complementary in Prognosis. Hematological Oncology. 2026. doi:10.1002/hon.70234
BibTeX
@article{Pan2026,
author = {Pan, Yubiao and Wang, Yue and Xiong, Yaqin and Li, Panpan and Yu, Chenqi and Liu, Peng},
title = {Early Serum Free Light Chain Response in Newly Diagnosed Multiple Myeloma: Documented Earlier Than MRD and Complementary in Prognosis},
journal = {Hematological Oncology},
year = {2026},
doi = {10.1002/hon.70234}
}
EUVIMED